- Home
- RNA
as 06-20-2025 4:00pm EST
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.4B | IPO Year: | 2020 |
| Target Price: | $68.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.51 - $56.00 | Next Earning Date: | 08-08-2025 |
| Revenue: | $8,927,000 | Revenue Growth: | -17.88% |
| Revenue Growth (this year): | -43.29% | Revenue Growth (next year): | 155.06% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | RNA | Chief Program Officer | Jun 2 '25 | Sell | $32.48 | 5,875 | $190,832.93 | 50,554 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | May 1 '25 | Sell | $32.40 | 5,875 | $190,324.15 | 50,554 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Apr 1 '25 | Sell | $27.83 | 5,875 | $163,485.98 | 50,554 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target
Insider Monkey
9 days ago
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Investing.com
10 days ago
Raymond James bullish on biotech firms on favorable valuation
PR Newswire
10 days ago
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
TipRanks
11 days ago
Avidity Biosciences price target raised to $75 from $65 at Chardan
Benzinga
11 days ago
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
PR Newswire
12 days ago
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
PR Newswire
12 days ago
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.